Smart drug delivery systems that are triggered by environmental conditions have been developed to enhance cancer therapeutic efficacy while limiting unwanted effects. Because cancer exhibits abnormally high local acidities compared to normal tissues (pH 7.4) due to Warburg effects, pH-sensitive systems have been researched for effective cancer therapy. Chitosan-based intelligent theragnosis nanocomposites, N-naphthyl-O-dimethymaleoyl chitosan-based drug-loaded magnetic nanoparticles (N Chitosan-DMNPs), were developed in this study. N Chitosan-DMNPs are capable of pH-sensitive drug release with MR-guided images because doxorubicin (DOX) and magnetic nanocrystals (MNCs) are encapsulated into the designed N-naphthyl-O-dimethymaleoyl chitosan (N-nap-O-MalCS). This system exhibits rapid DOX release as acidity increases, high stability under high pH conditions, and sufficient capacity for diagnosing and monitoring therapeutic responses. These results demonstrate that N Chitosan-DMNPs have potential as theragnosis nanocomposites for effective cancer therapy.

A fluorescence-based detection platform was developed for brain-derived neurotrophic factor (BDNF), a key biomarker of Alzheimer’s disease (AD). This platform utilizes localized surface plasmon resonance effects resulting from the interactions between silica-coated gold nanoparticles (Au@SiO₂) and enzymatically synthesized quantum dots (QDs). The gold nanoparticles were silica coated via the hydrolysis of tetraethyl orthosilicate, which allowed for precise control over the distance between the nanoparticles and QDs and refined the dynamics of fluorescence quenching and enhancement. Antibody conjugation was performed via sequential amination and carboxylation, followed by EDC/NHS coupling. BDNF was detected across a range of concentrations, from 1 ng/mL to 1 ng/mL, using an alkaline phosphatase (ALP)-conjugated polyclonal antibody targeting a secondary epitope of BDNF. The enzymatic hydrolysis of p-nitrophenyl phosphate by immobilized ALP led to the formation of cadmium sulfide QDs, with the fluorescence intensity correlating directly with the BDNF concentration. This platform offers a refined and precise method for detecting BDNF and is a reliable tool for the early diagnosis of AD.